Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Up – Should You Buy?

Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s share price gapped up prior to trading on Friday . The stock had previously closed at $25.40, but opened at $26.74. Capricor Therapeutics shares last traded at $26.6190, with a volume of 2,666,751 shares changing hands.

Analyst Ratings Changes

Several research analysts recently issued reports on CAPR shares. Industrial Alliance Securities set a $48.00 price target on shares of Capricor Therapeutics in a research report on Wednesday. Alliance Global Partners restated a “buy” rating on shares of Capricor Therapeutics in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a research note on Wednesday, October 8th. HC Wainwright boosted their price target on shares of Capricor Therapeutics from $24.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Roth Capital increased their price objective on shares of Capricor Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Capricor Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $31.30.

Capricor Therapeutics Stock Up 7.4%

The stock has a market cap of $1.25 billion, a P/E ratio of -15.07 and a beta of 0.61. The stock has a fifty day simple moving average of $7.19 and a 200-day simple moving average of $8.14.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.54) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.54). Sell-side analysts anticipate that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current year.

Hedge Funds Weigh In On Capricor Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CAPR. Geode Capital Management LLC increased its stake in Capricor Therapeutics by 6.8% during the 2nd quarter. Geode Capital Management LLC now owns 963,080 shares of the biotechnology company’s stock worth $9,565,000 after purchasing an additional 61,701 shares in the last quarter. Woodline Partners LP boosted its holdings in shares of Capricor Therapeutics by 15.8% in the first quarter. Woodline Partners LP now owns 729,318 shares of the biotechnology company’s stock valued at $6,921,000 after buying an additional 99,384 shares during the period. Pier Capital LLC boosted its holdings in shares of Capricor Therapeutics by 35.0% in the third quarter. Pier Capital LLC now owns 496,554 shares of the biotechnology company’s stock valued at $3,580,000 after buying an additional 128,837 shares during the period. Octagon Capital Advisors LP bought a new stake in shares of Capricor Therapeutics during the first quarter worth $4,270,000. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Capricor Therapeutics by 39.5% during the first quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock worth $3,902,000 after acquiring an additional 116,373 shares during the period. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.